You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Hi,
Thank you for developing this tool.
I would like to know if the CHEUI model can be applied to SARS-CoV-2?
I have obtained the result of solo outputs using CHEUI.
But almost all probability values are 0.013649046.
Only one DRACH site with probability 0.99999905.
In addition, I also have samples with Mettle3 inhibitors. Can I use CHEUI diff to detect the differences between the two samples?
Could someone give me some advice?
Best wishes,
Kirito
The text was updated successfully, but these errors were encountered:
Hi Kirito,
Yes, you can use CHEUI for whatever organism and RNA
We're using it systematically across all kingdoms of life
Yes, you can also use CHEUI-diff to compare between both conditions.
Those to A sites with high probability are encouraging.
CHEUI predicts in all sequence contexts, so the non-DRACH AGATG modified
site could be m6A, or other type of adenosine methylation. We saw that
nanopore does not distinguish well between m6A and m1A.
I hope this helps
Eduardo
Hi,
Thank you for developing this tool.
I would like to know if the CHEUI model can be applied to SARS-CoV-2?
I have obtained the result of solo outputs using CHEUI.
But almost all probability values are 0.013649046.
Only one DRACH site with probability 0.99999905.
In addition, I also have samples with Mettle3 inhibitors. Can I use CHEUI diff to detect the differences between the two samples?
Could someone give me some advice?
Best wishes,
Kirito
The text was updated successfully, but these errors were encountered: